passages: 3909
passages: document
passages: A double-blind , placebo-controlled study of fluvoxamine in adults with autistic disorder . BACKGROUND Autistic disorder is characterized by a fundamental disturbance in social interaction , impairments in communication , and a markedly restricted repertoire of activities and interests . Abnormalities in the serotonin neurotransmitter system have been identified in some persons with autism . No consistently effective and safe drugs have been developed for treating the symptoms of autism . METHODS Thirty adults with autistic disorder completed a 12-week double-blind , placebo-controlled trial of the potent and selective serotonin uptake inhibitor fluvoxamine maleate . Behavioral ratings were obtained at baseline and after 4 , 8 , and 12 weeks of treatment . RESULTS Eight ( 53 % ) of 15 patients in the fluvoxamine-treated group were categorized as responders compared with none of 15 in the placebo group ( P = .001 ) . Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior ( P < .001 ) , maladaptive behavior ( P < .001 ) , and aggression ( P < .03 ) , and in improving some aspects of social relatedness ( P < .04 ) , especially language usage ( P < .008 ) . Treatment response was not correlated with age level of autistic behavior , or full-scale IQ . Other than mild sedation and nausea in a few patients , fluvoxamine was well tolerated . No dyskinesias , adverse cardiovascular events , or seizures occurred . CONCLUSIONS Fluvoxamine is more effective than placebo in the short-term treatment of the symptoms of autistic disorder in adults . Controlled studies of fluvoxamine and other potent and selective serotonin uptake inhibitors seem warranted in children and adolescents with autism .
entities: 3910
entities: Intervention_Control
entities: placebo-controlled
entities: 3911
entities: Intervention_Pharmacological
entities: fluvoxamine
entities: 3912
entities: Intervention_Control
entities: placebo-controlled
entities: 3913
entities: Intervention_Pharmacological
entities: fluvoxamine maleate .
entities: 3914
entities: Intervention_Pharmacological
entities: fluvoxamine-treated
entities: 3915
entities: Intervention_Control
entities: placebo
entities: 3916
entities: Intervention_Pharmacological
entities: Fluvoxamine
entities: 3917
entities: Intervention_Control
entities: placebo
entities: 3918
entities: Intervention_Pharmacological
entities: fluvoxamine
entities: 3919
entities: Intervention_Pharmacological
entities: Fluvoxamine
entities: 3920
entities: Intervention_Control
entities: placebo
entities: 3921
entities: Intervention_Pharmacological
entities: fluvoxamine
entities: 3922
entities: Outcome_Mental
entities: Behavioral ratings
entities: 3923
entities: Outcome_Mental
entities: repetitive thoughts and behavior
entities: 3924
entities: Outcome_Mental
entities: maladaptive behavior
entities: 3925
entities: Outcome_Mental
entities: aggression
entities: 3926
entities: Outcome_Mental
entities: social relatedness
entities: 3927
entities: Outcome_Mental
entities: language usage
entities: 3928
entities: Outcome_Adverse-effects
entities: mild sedation and nausea
entities: 3929
entities: Outcome_Adverse-effects
entities: dyskinesias , adverse cardiovascular events , or seizures
entities: 3930
entities: Participant_Condition
entities: adults with autistic disorder .
entities: 3931
entities: Participant_Sample-size
entities: Thirty
entities: 3932
entities: Participant_Age
entities: adults
entities: 3933
entities: Participant_Condition
entities: autistic disorder